Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab Monotherapy in OA of Hip or Knee
NCT02289716Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of fulranumab in osteoarthritis (OA), sponsored by Janssen Pharmaceutical. Started Jul 2015; status: completed.
02
Drugs
fulranumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02289716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289716.